Welcome to our dedicated page for Bone Biologics news (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics stock.
Bone Biologics Corporation (NASDAQ: BBLG, BBLGW) is a biotechnology company developing orthobiologic products for spine fusion markets, with a focus on bone regeneration using NELL-1-based technology. This news page brings together company announcements and disclosures that highlight its scientific, clinical, operational and capital markets activities.
Readers can review updates on Bone Biologics’ lead product candidate NB1, which the company describes as a combination of recombinant human NELL-1 (rhNELL-1) and demineralized bone matrix for use as a bone graft in spinal fusion procedures. News items include descriptions of the company’s first-in-human clinical study in degenerative disc disease, where NB1 is being evaluated for safety and preliminary effectiveness in transforaminal lumbar interbody fusion.
Coverage also includes operational milestones such as extensions of rhNELL-1 shelf life from earlier 12- and 18-month validations to a reported 24-month validated shelf life, as well as formulation improvements intended to support scaled manufacturing. Intellectual property developments, including the filing of a U.S. patent application for compositions of rhNELL-1 polypeptide and uses in treating bone conditions, are documented in press releases.
Investors and observers can find information on public offerings of common stock and warrants, reverse stock split actions, and communications about Nasdaq listing compliance. The company’s participation in investor conferences and stockholder letters discussing clinical progress, manufacturing readiness, and outlook for NB1 are also reflected in the news flow. This page serves as a centralized source for Bone Biologics’ historical news, helping users follow its orthobiologic development program and related corporate events over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bone Biologics Corporation (NASDAQ: BBLG) has announced the approval of a multicenter pilot clinical trial for its NB1 bone graft by the Human Research Ethics Committee in Australia. The trial will enroll 30 adult patients undergoing transforaminal lumbar interbody fusion (TLIF) for degenerative disc disease (DDD). This study aims to assess the safety and effectiveness of NB1, which showed promising results in animal studies. The company aims to capture a part of the $3 billion global market for spine fusion products. Furthermore, the long-term goal includes addressing osteoporosis and trauma, potentially tapping into additional markets valued at $11 billion and $8 billion, respectively.
Bone Biologics Corporation (NASDAQ: BBLG) has engaged Avania as the Contract Research Organization (CRO) for its upcoming pilot clinical trial of NB1, targeting degenerative disc disease patients undergoing Transforaminal Lumbar Interbody Fusion (TLIF). The multicenter trial will assess the safety and effectiveness of the NB1 bone graft in 30 subjects, anticipated to start in late 2023, pending ethics committee approval from the Monash Health system in Australia. The inclusion of rhNELL-1 in the NB1 device is expected to enhance bone formation. CEO Jeffrey Frelick expressed optimism about moving into human testing with Avania's support.
Bone Biologics Corporation (NASDAQ: BBLG) has announced advancements in their lead product, NB1, utilizing NELL-1 for spinal fusion treatments. The global market for bone graft substitutes is estimated at
On October 13, 2022, WallachBeth Capital LLC announced the closure of an underwritten public offering for Bone Biologics (NASDAQ: BBLG), generating total gross proceeds of $5,100,000. The offering included 3,777,778 units at $1.35 per unit, each comprised of one share of common stock and three different Series warrants. The warrants have various exercise prices and expiration timelines, with some allowing cashless exercises. Underwriters were granted a 45-day option to purchase additional securities. The offering was made under an SEC registration statement that became effective on October 6, 2022.
Bone Biologics Corporation (NASDAQ: BBLG) has completed its underwritten public offering, raising
Bone Biologics Corporation (NASDAQ: BBLG) announced the pricing of an underwritten public offering of 3,777,778 units at $1.35 each, totaling $5,100,000 in gross proceeds. Each unit consists of one share of common stock and three types of warrants with varying exercise prices. The offering, managed by WallachBeth Capital, is set to close on or around October 11, 2022, pending customary conditions. Bone Biologics aims to utilize these funds for the development of its orthobiologic products, primarily focusing on spine fusion.